FeesSafety
Pluang+

Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial design for AI-driven drug REC-4881.

Market News
19 Nov 2026, 00:20 WIB
The Motley Fool
View Source
Bullish
Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial design for AI-driven drug REC-4881.

Recursion Pharmaceuticals' stock rose 3.86% to $2.83 following FDA alignment on the Phase 3 trial design for REC-4881, a treatment for familial adenomatous polyposis, a disease with no approved therapies. The FDA accepted a primary endpoint that could shorten and reduce the cost of the trial. The company sees a $15 billion market opportunity with over 50,000 patients in the U.S. and E.U. The Phase 3 trial will start in the second half of 2027, and success could validate both the drug and Recursion's AI drug discovery platform. Investors should be patient and cautious as the trial results are still pending.

Recursion Pharmaceuticals (RXRX) trades at $2.81 on Pluang as of Nov 19, 2026 05:11 WIB, slightly below its 52-week high of $4.96. The stock gained 3.31% in one day, with 63% of Pluang orders buying. The typical hold time for RXRX on Pluang is 23 days, showing moderate investor interest.

More News (RXRX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App